netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Formulary Chapter 6: Endocrine system - Full Section
Notes:

Chapter review date:

Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
06.01 Drugs used in diabetes (0,1)
06.01.01 Insulins (2,0)
06.01.01.01 Short-acting insulins (0,5)
Soluble Insulin (2,0)
Rapid Acting Insulin Analogues (6,0)
Ultra-Rapid acting insulin analogues (0,0)
Short-acting human insulin analogues (0,0)
06.01.01.02 Intermediate- and long-acting insulins (0,6)
Biphasic insulins (0,3)
Intermediate Acting Insulin (6,0)
Long Acting Insulin Analogues (5,0)
06.01.01.03 Hypodermic equipment (0,0)
Needles (0,0)
Lancets (0,0)
06.01.02 Antidiabetic drugs (0,0)
06.01.02.01 Sulphonyureas (5,3)
06.01.02.02 Biguanides (2,0)
06.01.02.03 Other antidiabetic drugs (0,10)
DPP-4 inhibitors (3,0)
Alpha glucosidase inhibitors (0,0)
GLP-1 mimetics (5,0)
DPP4 inhibitors (gliptins) (0,0)
SGLT2 inhibitors (3,0)
GLP1 agonists (0,0)
Meglitinides (0,0)
SGL2 inhibitors (0,0)
Other (2,0)
Thiazolidinediones (0,0)
Glucagon-like peptide-1 receptor agonists - once weekly (0,0)
06.01.02.07 Other antidiabetic drugs (0,0)
06.01.03 Diabetic ketoacidosis (0,0)
06.01.04 Treatment of hypoglycaemia (3,1)
Chronic hypoglycaemia (1,0)
06.01.05 Treatment of diabetic nephropathy and neuropathy (0,0)
Diabetic nephropathy (0,0)
Diabetic neuropathy (0,0)
06.01.06 Diagnostic and monitoring agents for diabetes mellitus (0,0)
Blood glucose monitoring (Formulary traffic light status applies to Type 2 patients only) (11,0)
Urinalysis (2,18)
Oral glucose tolerance test (0,2)
06.02 Thyroid and Antithyroid drugs (0,0)
06.02.01 Thyroid hormones (3,1)
06.02.02 Antithyroid drugs (4,0)
06.03 Corticosteroids (0,0)
06.03.01 Replacement therapy (1,0)
06.03.02 Glucocorticoid therapy (9,4)
06.04 Sex hormones (0,0)
06.04.01 Female sex hormones and their modulators (0,1)
06.04.01.01 Oestrogens and HRT (18,28)
Hormone replacement therapy (0,0)
Ethinylestradiol (0,2)
Raloxifene (1,1)
Oestrogen only tablets (0,0)
Oestrogens and progestogen sequential combined therapy (0,0)
Continuous combined therapy (0,0)
Gonadomimetic (0,0)
Selective oestrogen modulator (0,0)
06.04.01.02 Progestogens (5,1)
06.04.02 Male sex hormones and antagonists (3,5)
Anti-androgens (3,0)
Dutasteride and finasteride (0,0)
06.04.03 Anabolic steroids (0,1)
06.04.04 Gender dysphoria (0,0)
06.05 Hypothalamic and pituitary hormones and anti-oestrogens (0,0)
06.05.01 Hypothalamic and anterior pituitary hormones and anti-oestrogens (0,0)
Anti-oestrogens (1,0)
Anterior pituitary hormones (8,4)
Gonadotrophins (0,0)
Growth Hormone (0,0)
Growth hormone receptor antagonists (0,0)
Thyrotropin (0,0)
Hypothalmic hormones (1,1)
06.05.02 Posterior pituitary hormones and antagonists (0,0)
Posterior pituitary hormones (4,1)
Antidiuretic hormone antagonists (3,0)
06.06 Drugs affecting bone metabolism (0,0)
Osteoporosis (0,0)
06.06.01 Calcitonin and parathyroid hormone (4,0)
06.06.02 Bisphosphonates and other drugs affecting bone metabolism (0,0)
Bisphosphonates (8,5)
Denosumab (2,0)
Strontium renelate (0,1)
06.07 Other endocrine drugs (1,0)
06.07.01 Bromocriptine and other dopaminergic drugs (2,1)
06.07.02 Drugs affecting gonadotrophins (1,3)
Gonadorelin analogues (5,0)
Breast pain (mastalgia) (0,0)
06.07.03 Metyrapone (1,1)
06.07.04 Somatomedins (1,0)
netFormulary